PATENT ABSTRACTS 3Ol

4806629 4810634

M O N O C L O N A L A N T I B O D Y T O A H U M A N T H Y M O C Y T E A N T I G E N

Patrick C Kung, Gideon Goldstein assigned to Ortho Pharmaceutical Corporation

Hybrid cell line for production of monoclonal antibody to an antigen found on approximately 70% of normal human thymocytes. The hybrid is formed by fusing splenocytes from immunized CAF1 mice with P3X63Ag8UI myeloma cells. Diagnostic and therapuetic uses of the mono- clonal antibody are also disclosed.

P S E U D O R A B I E S V I R U S M U T A N T S I N C A P A B L E O F

P R O D U C I N G G L Y C O P R O T E I N X

Leonard Post, Darrell R Thomsen assigned to The Upjohn Company

Provided are a virus vaccine, comprising a pro- perly incapacitated virus lacking an antigen of the wild-type virus which is useful for serologically distinguishing between vaccinated and infected animals, methods for distinguishing between vaccinated and infected animals and multivalent vaccines.

4810491

P O L Y P E P T I D E S U S E F U L I N V A C C I N A T I O N A G A I N S T

E N T E R O V I R U S E S

Philip D Minor, David M Evans, Geoffrey C Schild, Jeffrey W Almond, London, United Kingdom assigned to National Research Development Corporation

A synthetic polypeptide, suitable for use in vac- cination against or diagnosis of a disease caused by an enterovirus, is an octapeptide coded for by codons 93-100 in the RNA sequence coded for the structural capsid protein VP1 for poliovirus type 3 Sabin strain or by equivalent codons of another enterovirus or is an antigenic equivalent of such an octapeptide, the numbers of the codons being counted from the 5'-terminus of the nucleotide sequence for the VP1 capsid pro- tein.

4810494

C A N I N E P A R V O V I R U S V A C C I N E S

Jill Welsh, Houghton, United Kingdom assigned to Akzo N V

The present invention concerns a vaccine com- prising a novel canine parvovirus strain and having the property of being able to break through the maternally derived antibody levels persistent in 9-12 week old pups, and even to im- munize the majority of pups at the age of 6 weeks in the presence of maternally derived antibodies.

4812449

I N S I T U A C T I V E C O M P O U N D A S S E M B L Y

Darryl C Rideout assigned to Scripps Clinic and Research Foundation

Differences in microenvironments associated with various cells and other conditions in this en- vironment are used to advantage in effecting the in situ construction of biologically active agents at target locations in preference to surroundings which are desired to be unaffected.

4812554

S O M A T O S T A T I N P E P T I D E C O N J U G A T E

Arthur D Riggs assigned to Genentech Inc

The specification discloses: 1. Recombinant microbial cloning vehicles comprising hetero- logous DNA coding for the expression of mam- malian hormone (e.g., somatostatin) and other polypeptides, including plasmids suited for the transformation of bacterial hosts. The latter in- corporate a regulon homologous to the host in its untransformed state, in reading phase with the structural gene for the heterologous DNA; 2. Cloning vehicles coding for the microbial expres- sion of a protein variously comprising (a) a poly- peptide hapten and additional protein sufficient in size to confer immunogenicity on the product of expression, which may find use in raising anti- bodies to the hapten for assay use or in the manufacture of vaccines; and (b) a desired poly- peptide product and additional protein from which the desired product may be cleaved; and 3. Methods of preparing synthetic structural genes coding for the expression of mammalian poly- peptides in microbial cloning systems.